Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19중증 COVID-19 환자 치료에서 토실리주맙과 메틸프레드니솔론의 효능 및 안전성 비교Article Published on 2022-06-012022-09-11 Journal: International immunopharmacology [Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료기술, 치료법, [키워드] 28-day mortality 95% CI adverse event adverse events alternative caused clinical clinical response comparable COVID Cox regression analysis CRP Dexamethasone dose doses duration of hospitalization Efficacy and safety faster group groups hospitalized patient hospitalized patients ICU admission improvement intravenous methylprednisolone Methylprednisolone not significantly different occurred Other outcome oxygen oxygen saturation Patient Primary outcome problem prospective cohort study secondary Secondary outcomes severe COVID-19 Sleep disturbance Sleep disturbances statistically significant Tocilizumab Treatment were recorded [DOI] 10.1016/j.intimp.2022.108689 PMC 바로가기 [Article Type] Article
Efficacy and safety of HD-tDCS and respiratory rehabilitation for critically ill patients with COVID-19 The HD-RECOVERY randomized clinical trialRandomized Controlled Trial Published on 2022-05-012022-10-05 Journal: Brain stimulation [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 acute respiratory distress syndrome addition Adverse adverse effect attenuate Brain clinical response conducted coronavirus disease corticospinal COVID-19 Critically ill patient current defined delirium Direct Direct Current distress dysfunction Efficacy Efficacy and safety evaluate event fatigue feasible groups High-definition transcranial direct current stimulation hospital impairment increase in intensive care Intervention investigated mechanical ventilation moderate Mortality no significant difference Noninvasive brain stimulation organ dysfunction Organ failure pathway patients patients with COVID-19 patients with moderate positive Primary outcome Randomized randomized clinical trial rehabilitation respiratory respiratory rehabilitation Safe secondary outcome severe ARDS severe hypoxemia statistically significant Stimulation therapy Trial unit discharge ventilator-free day with COVID-19 [DOI] 10.1016/j.brs.2022.05.006 PMC 바로가기 [Article Type] Randomized Controlled Trial
Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patientsObservational Study Published on 2022-04-012022-10-04 Journal: Journal of Nephrology [Category] COVID19(2023년), SARS, 임상, [키워드] administration age appear Barcelona BNT162b2 booster dose Cellular responses clinical Clinical efficacy clinical response COVID-19 death defined diagnosed dialysis died dose Efficacy Haemodialysis highlight Hospital admission hospitalizations humoral ICU admission Infection information invasive kidney transplant kidney transplant recipient Kidney transplantation Male sex mechanical ventilation Moderna mRNA mRNA SARS-CoV-2 vaccination. mRNA vaccine mRNA vaccines mRNA-1273 Non-invasive outcome Patient patients Pfizer-BioNTech Population positive RT-PCR Prospective Study required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination severe COVID-19 significantly higher Spain vaccination vaccine dose were infected [DOI] 10.1007/s40620-022-01257-5 PMC 바로가기 [Article Type] Observational Study
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer Research Published on 2022-03-172022-10-05 Journal: Nature cancer [Category] 변종, 유전자 메커니즘, [키워드] Antigen binding blockade Breast cancer Cancer stem cell cell differentiation clinical response Combination driving Efficacy element expression Extracellular generate Genetic heterogeneity IFN Immune escape Immunotherapy ISREs LCOR Metastasis Modification modulation phenotypic reduced RNA Support therapy These data transcriptional Vesicle [DOI] 10.1038/s43018-022-00339-4 [Article Type] Research
Evaluation of the genetic risk for COVID-19 outcomes in COPD and differences among worldwide populationsResearch Article Published on 2022-02-232022-10-28 Journal: PLoS ONE [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] acute respiratory syndrome African allele alleles allelic allelic combination Analysis Asian build Case-control characterized chronic obstructive clinical response clinically Cohort conducted contributing to control group COPD coronavirus COVID-19 COVID-19 infection COVID-19 susceptibility Diseases distribution European European population finding Frequency Genetic genetic background genetic heterogeneity genetic map Genetic predisposition genetic risk genotyped global pandemic groups heterogeneity Hospitalization Infection Italian outcome P-value people with COPD Phenotypes poor prognosis Population populations predisposition Probability Prognosis pulmonary disease recent Respiratory failure respond risk risk allele Risk scores rs657152 Saliva severe COVID-19 severity significant difference SNP Spanish survival susceptibility used to calculate Variability was performed were assessed [DOI] 10.1371/journal.pone.0264009 PMC 바로가기 [Article Type] Research Article
COVID-19 Treatments Sold Online Without Prescription Requirements in the United States: Cross-sectional Study Evaluating Availability, Safety and Marketing of Medications미국에서 처방전 없이 온라인으로 판매되는 COVID-19 치료제: 의약품의 가용성, 안전성 및 마케팅을 평가하는 횡단면 연구Original Paper Published on 2022-02-162022-09-10 Journal: Journal of Medical Internet Research [Category] COVID19(2023년), SARS, 치료제, [키워드] adverse effects Care Characteristics claimed clinical evidence clinical response conducted counseling COVID-19 COVID-19 pandemic COVID-19 treatment COVID-19 treatments cross-sectional cross-sectional study demonstrated Dexamethasone drug Drug interactions effective Efficacy English evaluated Evaluating Evidence Google Health Health care highlight Hydroxychloroquine hydroxychloroquine) Identified Internet lack Lopinavir Lopinavir-ritonavir measure medication medications Medicines mimicking MONITOR objective offer offered online pharmacy pandemic patients Pharmacy potential COVID-19 treatments prescription Prescriptions professional required Requirement Result Ritonavir Safety Safety measures scientific evidence seeking self-treatment Support the United State treat Treatment unique United States website were recorded Yahoo! [DOI] 10.2196/27704 PMC 바로가기 [Article Type] Original Paper
Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital동적 시간 왜곡 분석을 사용한 바이오마커 식별: 영국 3차 병원의 COVID-19 환자에 대한 종단 코호트 연구Article Published on 2022-02-152022-09-11 Journal: BMJ Open [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] Admission Analysis association biochemical biochemical parameter blood tests board C reactive protein change clinical benefit clinical feature clinical response clinical utility COVID-19 CRP D-dimer decrease decreases described determined by discharge discharged disease Disease progression East England Ethical approval ferritin healthcare heterogeneous high mortality highest hospital hospitalised patient Hospitalised patients HRA increase Increases information Informed consent Laboratory Lactate lactate dehydrogenase limit longitudinal change longitudinal changes longitudinal cohort study lowest lymphocyte Lymphocyte count majority Mortality Most patients neutrophil neutrophil counts outcome pandemic Patient patients patients treated patients with COVID-19 Platelet platelet counts prognostic prognostic variable REC respiratory respiratory infections respiratory medicine (see thoracic medicine) retrospective review risk routine blood test routine blood tests SARS-CoV-2 South Specific symptom onset Thoracic Treatment response urea Variation variations waiver was obtained white cell with COVID-19 [DOI] 10.1136/bmjopen-2021-050331 PMC 바로가기 [Article Type] Article
Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trialRandomized Controlled Trial Published on 2022-02-012022-10-05 Journal: Pharmacological Reports [Category] 임상, [키워드] 95% CI adverse effect adverse event Analysis assigned clinical clinical response competing COVID-19 death Dexamethasone Diagnosis different dose dose Efficacy Efficacy and safety groups High-dose high-dose group hospital discharge hospitalized patient hyperglycemia IMPROVE incidence increase in Intermediate-dose intravenous low-dose moderate not significantly different outcome Patient randomized clinical trial risk severe COVID-19 Side effect significantly survival Treatment with COVID-19 [DOI] 10.1007/s43440-021-00341-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19Article Published on 2022-01-232023-07-02 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, [키워드] ALT, alanine transaminase ARDS, acute respiratory distress syndrome AST, Aspartate transaminase clinical response COVID-19 COVID-19, Coronavirus disease 2019 CRP, C-reactive protein early initiation ePO2/FiO2, estimated arterial oxygen/fraction of inspired oxygen ratio HCQ, hydroxychloroquine ICU, Intensive care unit IFN-β, interferon-β IL-6, Interleukin-6 IMV, invasive mechanical ventilation IQR, interquartile range LDH, lactate dehydrogenase LPV/r, Lopinavir/ritonavir NAT, nucleic acid testing OTR, oxygen therapy requirements predictors RT-PCR, Reverse Transcription-Polymerase Chain Reaction SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 SCI, Significant clinical improvement TCZ, tocilizumab Tocilizumab [DOI] 10.1016/j.ijid.2022.01.040 PMC 바로가기 [Article Type] Article
Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case reportCase Report Published on 2022-01-152022-10-27 Journal: BMC Gastroenterology [Category] COVID-19, [키워드] acute respiratory syndrome adjusted Admission Case report clinical response Clinical symptoms clinician coronavirus cortisone cortisone therapy Course COVID-19 COVID-19 pneumonia defined discharged dose High-dose hospital IBD Immunosuppression IMPROVE increased risk induction infected patient Infection Inflammatory Inflammatory bowel disease inhibitor initiated intravenous managing medication outbreak pandemic Patient patients positive Prednisolone presenting regimen risk SARS-CoV-2 severe coronavirus disease Symptoms the patient therapeutic option therapy treat Treatment ulcerative colitis viral infection viral reactivation was tested [DOI] 10.1186/s12876-022-02094-3 PMC 바로가기 [Article Type] Case Report